A batch of abstracts released on a Thursday afternoon ahead of the ASCO 2026 oncology conference offered an early look at data spanning multiple drug classes drawing significant industry attention, according to reporting by Endpoints News.
TROP2 ADC Competition
Among the disclosures, Merck and Kelun-Biotech's TROP2-targeting antibody-drug conjugate, designated sac-TMT, featured prominently. TROP2-directed ADCs have become an increasingly crowded field in oncology, with several programs advancing through clinical development in breast and lung cancer indications. The sac-TMT abstract added a further data point to that competitive landscape ahead of formal presentation at the conference.
VEGF Bispecific Race
Data from the VEGF bispecific space was also flagged as a notable disclosure in the abstract release. Bispecific antibodies targeting VEGF-related pathways represent an area of active development, with multiple companies working to establish differentiation in efficacy and safety profiles. The ASCO abstracts were reported to include findings relevant to that ongoing competition.
Gilead's Tubulis Program
Gilead's program developed in partnership with Tubulis was separately reported as part of the ASCO 2026 data slate. The Tubulis collaboration centers on next-generation ADC linker-payload technology, and the appearance of associated data at a major oncology congress marks a continued step forward for that program's clinical profile.
Next-Generation CDK4/6 Inhibitors
The abstracts also touched on developments in the CDK4/6 inhibitor class, specifically candidates positioned as potential successors to Pfizer's palbociclib, marketed as Ibrance. Palbociclib was among the first CDK4/6 inhibitors to reach widespread clinical use in hormone receptor-positive breast cancer, and a cohort of next-generation agents has since emerged seeking to improve on its efficacy, tolerability, or resistance profile. The ASCO abstract slate appears to include data relevant to that generational transition within the class.
The full presentations associated with these abstracts are expected to follow at the ASCO 2026 meeting. Abstract releases ahead of major oncology conferences typically provide an initial signal of trial outcomes, though complete datasets and formal analyses are generally reserved for the conference sessions themselves.